Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Accumulated Expenses (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Other Accumulated Expenses for 14 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses fell 3.72% year-over-year to $1.6 million, compared with a TTM value of $1.6 million through Dec 2025, down 3.72%, and an annual FY2025 reading of $1.6 million, down 3.72% over the prior year.
  • Other Accumulated Expenses was $1.6 million for Q4 2025 at Karyopharm Therapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $7.1 million in Q4 2023 and bottomed at $524000.0 in Q2 2021.
  • Average Other Accumulated Expenses over 5 years is $2.0 million, with a median of $1.8 million recorded in 2022.
  • The sharpest move saw Other Accumulated Expenses soared 285.44% in 2023, then crashed 76.96% in 2024.
  • Year by year, Other Accumulated Expenses stood at $678000.0 in 2021, then skyrocketed by 172.57% to $1.8 million in 2022, then skyrocketed by 285.44% to $7.1 million in 2023, then plummeted by 76.96% to $1.6 million in 2024, then fell by 3.72% to $1.6 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for KPTI at $1.6 million in Q4 2025, $1.8 million in Q3 2025, and $1.6 million in Q2 2025.